1. Lexicon Pharmaceuticals
This company s lead drug, sotagliflozin, earned approval in the EU a couple of years ago, but the FDA raised concerns that kept it from reaching U.S. pharmacy shelves. Lexicon Pharmaceuticals stock jumped last week when the company told investors the FDA is willing to review a new application supported by results from the Soloist and Scored trials for a much larger indication than type 1 diabetes, as originally planned.
Image source: Getty Images.
Sotagliflozin is a drug that reduces blood sugar concentrations for diabetes patients by allowing glucose to pass through the kidneys and exit the body via the urinary tract. Cardiovascular disease is the leading co-morbidity for millions of type 2 diabetes patients, and a drug that prevents heart problems for people at high risk could earn billions annually.
The only EV stock I ll buy
I ve said before that General Motors is the only electric vehicle stock I ll put my own money into. That s for a good reason. The massive automaker is still in the early stages of ramping up its EV production with its much-anticipated Hummer electric pickup set to be released next year. This is just the beginning. GM recently announced that it plans to hire 3,000 new engineers to build out its electric vehicle production and that it plans to launch 30 electric models by 2025.
Image source: Getty Images.
GM has deep pockets to invest in electric and autonomous technology, and its brand loyalty gives it a big competitive advantage. It could emerge as one of the big players in the EV race. At less than seven times expected 2021 earnings, it s too cheap to ignore.